- Home
- BMRN vs EVR Comparison
BMRN vs EVR Comparison
Compare BMRN & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- EVR
- Stock Information
- Founded
- BMRN 1996
- EVR 1995
- Country
- BMRN United States
- EVR United States
- Employees
- BMRN N/A
- EVR N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- EVR Investment Managers
- Sector
- BMRN Health Care
- EVR Finance
- Exchange
- BMRN Nasdaq
- EVR Nasdaq
- Market Cap
- BMRN 11.1B
- EVR 11.6B
- IPO Year
- BMRN 1999
- EVR 2006
- Fundamental
- Price
- BMRN $54.65
- EVR $323.44
- Analyst Decision
- BMRN Buy
- EVR Buy
- Analyst Count
- BMRN 20
- EVR 8
- Target Price
- BMRN $92.21
- EVR $316.25
- AVG Volume (30 Days)
- BMRN 2.2M
- EVR 443.5K
- Earning Date
- BMRN 10-28-2025
- EVR 10-22-2025
- Dividend Yield
- BMRN N/A
- EVR 1.04%
- EPS Growth
- BMRN 154.69
- EVR 52.07
- EPS
- BMRN 3.40
- EVR 11.01
- Revenue
- BMRN $3,063,608,000.00
- EVR $3,238,871,000.00
- Revenue This Year
- BMRN $13.35
- EVR $18.25
- Revenue Next Year
- BMRN $9.18
- EVR $22.87
- P/E Ratio
- BMRN $16.09
- EVR $29.43
- Revenue Growth
- BMRN 18.36
- EVR 23.41
- 52 Week Low
- BMRN $52.48
- EVR $148.63
- 52 Week High
- BMRN $73.51
- EVR $364.42
- Technical
- Relative Strength Index (RSI)
- BMRN 47.87
- EVR 41.62
- Support Level
- BMRN $53.19
- EVR $318.73
- Resistance Level
- BMRN $54.50
- EVR $339.04
- Average True Range (ATR)
- BMRN 1.20
- EVR 10.55
- MACD
- BMRN 0.29
- EVR -3.97
- Stochastic Oscillator
- BMRN 62.43
- EVR 8.92
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About EVR Evercore Inc.
Evercore Inc is an independent investment bank that derives the majority of its revenue from financial advisory, including merger, acquisition, and restructuring advisory. It also has institutional equities trading, equity underwriting, and investment management businesses that account for around 20% of net revenue. The company was founded in 1996 and went public in 2006. Evercore had approximately 2,380 employees at the end of 2024, and about 75% of its revenue is derived from the United States.